Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response
Open Access
- 9 May 2005
- journal article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 201 (10), 1591-1602
- https://doi.org/10.1084/jem.20042167
Abstract
A major barrier to successful antitumor vaccination is tolerance of high-avidity T cells specific to tumor antigens. In keeping with this notion, HER-2/neu (neu)-targeted vaccines, which raise strong CD8+ T cell responses to a dominant peptide (RNEU420-429) in WT FVB/N mice and protect them from a neu-expressing tumor challenge, fail to do so in MMTV-neu (neu-N) transgenic mice. However, treatment of neu-N mice with vaccine and cyclophosphamide-containing chemotherapy resulted in tumor protection in a proportion of mice. This effect was specifically abrogated by the transfer of neu-N–derived CD4+CD25+ T cells. RNEU420-429-specific CD8+ T cells were identified only in neu-N mice given vaccine and cyclophosphamide chemotherapy which rejected tumor challenge. Tetramer-binding studies demonstrated that cyclophosphamide pretreatment allowed the activation of high-avidity RNEU420-429-specific CD8+ T cells comparable to those generated from vaccinated FVB/N mice. Cyclophosphamide seemed to inhibit regulatory T (T reg) cells by selectively depleting the cycling population of CD4+CD25+ T cells in neu-N mice. These findings demonstrate that neu-N mice possess latent pools of high-avidity neu-specific CD8+ T cells that can be recruited to produce an effective antitumor response if T reg cells are blocked or removed by using approaches such as administration of cyclophosphamide before vaccination.Keywords
This publication has 48 references indexed in Scilit:
- A listing of human tumor antigens recognized by T cells: March 2004 updateCancer Immunology, Immunotherapy, 2004
- CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curativeEuropean Journal of Immunology, 2004
- Antigen-dependent Proliferation of CD4+ CD25+ Regulatory T Cells In VivoThe Journal of Experimental Medicine, 2003
- Control of Regulatory T Cell Development by the Transcription Factor Foxp3Science, 2003
- The enemy within: keeping self-reactive T cells at bay in the peripheryNature Reviews Immunology, 2002
- Studying cancer in the mouseOncogene, 1999
- Phenotypic Analysis of Antigen-Specific T LymphocytesScience, 1996
- Cyclophosphamide and abrogation of tumor-induced suppressor T cell activityCancer Immunology, Immunotherapy, 1990
- The murine MHC class I genes, H-2Dq and H-2Lq, are strikingly homologous to each other, H-2Ld, and two genes reported to encode tumor-specific antigens.The Journal of Experimental Medicine, 1988
- Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.The Journal of Experimental Medicine, 1982